Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...
On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also ...
Bill Sibold, Chief Executive Officer of Madrigal, stated, “NASH with moderate to advanced liver fibrosis is a serious and progressive liver disease that, until now, has not had an FDA-approved therapy ...
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--Phase 2 clinical results with HTD1801, a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while ...
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic ...
The younger, seemingly fit population is increasingly being afflicted with lean fatty liver disease due to hidden visceral ...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and if it is accurately predicted ...
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) The Rezdiffra prescribing information does not include a liver biopsy requirement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback